About

Sexton Riley LLP is a boutique Boston law firm
specializing in collaborations and other strategic transactions for life sciences companies.

Mike Sexton is a corporate lawyer with over 20 years of experience representing life sciences and health care clients in a range of strategic transactions and regulatory matters.

Before co-founding Sexton Riley LLP in 2015, Mike was a partner in the Life Sciences and Health Care Groups of the global law firm Ropes & Gray LLP. While at Ropes & Gray, Mike represented Johnson & Johnson, Pfizer, Biogen, AstraZeneca, RiverVest Venture Partners, Alexion Pharmaceuticals, Verax Biomedical, Salient Surgical Technologies and other life sciences clients. He also represented health care clients such as Yale University School of Medicine, Stanford University School of Medicine and Hospitals, and Express Scripts.

Mike is a graduate of Amherst College and Harvard Law School.

Lindsay Riley is a corporate lawyer with over 7 years of experience representing life sciences clients in a range of strategic and intellectual property transactions. Before co-founding Sexton Riley LLP in 2015, Lindsay was a senior associate in the Life Sciences Group of Ropes & Gray LLP, where she represented Johnson & Johnson, Biogen, Sanofi, Alexion Pharmaceuticals and other life sciences clients. Lindsay is registered to practice before the USPTO in patent matters.

Lindsay is a graduate of Northeastern University and Northeastern University School of Law.

Mike and Lindsay’s collaboration and strategic transaction experience includes:

For Johnson & Johnson and its affiliates:
- Collaboration and license agreement with Pharmacyclics for oncology drug Imbruvica
- Collaboration agreements with Gilead and ViiV Healthcare for HIV drug combination regimens
- Divestiture of U.S. Nucynta rights to Depomed
- Strategic collaboration agreement with enGene for new IBD therapies
- Collaboration and license agreement with Macrogenics for MGD011
- Acquisition of Aragon Pharmaceuticals
- Remicade and Simponi distribution agreement amendment and settlement with Merck
- Doxil manufacturing agreement with Ben Venue Laboratories
- Spinout of and license agreement with Movetis NV
- Collaboration and license agreement and co-promotion agreements with Millennium Pharmaceuticals (Takeda) for Velcade
For other life sciences clients:
- Biogen’s acquisition of worldwide rights to Tysabri from Elan Pharmaceuticals
- Genzyme's strategic alliance with Alnylam Pharmaceuticals for RNAi therapeutics
- Alexion’s collaboration agreement with Moderna Therapeutics for messenger RNA therapeutics
- Agreements for manufacturing and supply, distribution, co-promotion, sponsored research, compound library screening, Rx-to-OTC switches and authorized generics for various pharmaceutical, biotech and medical device companies.
Venture capital financings and related transactions for RiverVest Venture Partners and its affiliates, including investments in Lyric Pharmaceuticals, Smart Wires, Excaliard Pharmaceuticals, Lumena Pharmaceuticals, Tryton Medical, Accumetrics, Calypso Medical and Lutonix.

Awards:
Super Lawyers - Rising Stars 2016 - Technology Transactions, Intellectual Property - Lindsay Riley
Best Lawyers in America (2016)
U.S. News Best Law Firms (2015, 2016)
Chambers USA: America's Leading Lawyers for Business